• Adagio Medical highlighted vCLAS, an ultra-low temperature cryoablation catheter aimed at ventricular tachycardia ablation, with FDA approval targeted for Q4 2026 and a limited US launch planned for Q1 2027.
• Company presented FULCRUM-VT pivotal study metrics including 2.4% major adverse event rate, 84% freedom from ICD shock at 6 months, 72% reduction or elimination of antiarrhythmic drugs at 6 months.
• Next-generation vCLAS Ultra sub-study was outlined with enrollment completion targeted for Q3 2026, PMA supplement submission targeted for Q1 2027, approval targeted for 2H 2027.
• VT ablation global total addressable market was estimated at USD 5.8 billion, with about 6% penetration based on about 100,000 current procedures.
• Balance sheet snapshot as of 03/31/26 showed cash and cash equivalents of USD 12.9 million, convertible notes payable of USD 22.9 million, shares outstanding of 22,200,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.